**Reviews**

[35] Sørensen P, Jønsson A, Mathiesen H, Blinkenberg M, Andresen J, Hanson L, Rav‐ nborg M. The relationship between MRI and PET changes and cognitive disturbances

[36] The Royal College of Physicians and The Royal College of Radiologists. Evidencebased indications for the use of PET-CT in the UK. London: RCP, RCR, 2013.

[37] Tian L, Ma L, Kaarela T, Li Z. Neuroimmune crosstalk in the central nervous system and its significance for neurological diseases. J Neuroinflamm, 2012; 9:155.

[38] van Gaalen J, van de Warenburg B. A practical approach to late-onset cerebellar atax‐

[39] Vincent A, Bien C, Irani S, Waters P. Autoantibodies associated with diseases of the CNS: New developments and future challenges. Lan Neurol, 2011; 10:759-772.

[40] Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for

[41] Wang P, Liu R, Yang B, Soong B. Regional patterns of cerebral glucose metabolism in spinocerebellar ataxia type 2, 3 and 6: A voxel-based FDG-positron emission tomog‐

[42] Wraith D, Nicholson L. The adaptive immune system in diseases of the central nerv‐

[43] Wu C, Li F, Niu G, Chen X. PET imaging of inflammation biomarkers. Theranostics,

[44] Zanzonico P. Principles of nuclear medicine imaging: Planar, SPECT, PET, multi-mo‐ dality, and autoradiography systems. Radiation Reseach, 2012; 177:349-364.

in MS. J Neurol Sci, 2006; 245(1-2):99-102.

52 Immunopathology and Immunomodulation

ia. Pract Neurol, 2012; 12(1):14-24.

PET/CT. Eur J Radiol, 2010; 73:461-469.

2013; 3:448-466.

raphy analysis. J Neurol, 2007; 254(7):838-45.

ous system. J Clin Invest, 2012; 122(4):1172-1179.
